march
number
laboratori
independ
report
isol
character
novel
coronaviru
cov
specimen
patient
sever
acut
respiratori
syndrom
sar
although
effect
therapeut
strategi
sar
yet
develop
interferon
ifn
recogn
play
critic
role
host
resist
viral
infect
therebi
implic
potenti
candid
sar
cov
treatment
ifn
inhibit
viral
infect
directli
interf
viral
replic
induc
innat
adapt
immun
respons
infect
effect
treatment
hepat
b
c
respiratori
coronaviru
infect
unrel
urbani
strain
sarscov
combin
effect
inhibit
sarscov
replic
vitro
moreov
report
macacqu
monkey
protect
infect
sar
cov
treatment
ifn
infergen
intermun
corp
brisban
california
synthet
design
repres
consensu
shown
cell
cultur
system
compar
clinic
trial
inhibit
viral
replic
potent
base
find
pilot
studi
evalu
potenti
clinic
benefit
safeti
ifn
sar
treatment
conduct
laboratori
patient
treat
ifn
corticosteroid
shorter
time
resolut
lung
radiograph
abnorm
better
oxygen
satur
resolv
need
supplement
oxygen
rapidli
compar
group
receiv
corticosteroid
alon
bind
activ
type
ifn
receptor
ifnar
high
affin
bind
ifn
ifnar
induc
associ
two
receptor
chain
subsequ
reciproc
transphosphoryl
activ
associ
janu
kinas
jak
jakstat
signal
transduc
activ
transcript
pathway
induc
ifnmedi
signal
transduct
transcript
activ
requir
antivir
respons
recent
year
becom
appar
activ
ifnrassoci
jak
also
regul
multipl
downstream
signal
transduc
molecul
mitogen
activ
protein
kinas
mapk
crkl
phosphatidylinositol
kinas
protein
kinas
c
famili
pkc
vav
protooncogen
signal
divers
consist
pleiotrop
biolog
effect
ifn
target
cell
tissu
mous
hepat
virus
mhv
type
coronavirus
typic
caus
pneumon
enceph
entercol
hepat
phylogenet
data
suggest
sarscov
distinct
group
coronaviru
previou
studi
shown
provid
protect
infect
vivo
ongo
experi
evid
inject
intranas
mice
induc
lung
infect
indistinguish
sarscov
infect
human
g
levi
et
al
uhn
unpublish
specif
aj
mice
highli
suscept
intranas
infect
develop
pulomonari
diseas
character
mark
pulmonari
congest
hyalin
membran
interstiti
thicken
inflamm
alveolar
exud
similar
sar
lung
diseas
human
accordingli
understand
mechan
action
ifn
limit
sarscov
infect
human
develop
vitro
model
system
use
murin
lung
fibroblast
cell
permiss
infect
report
provid
evid
direct
antivir
effect
identifi
sever
signal
effector
mediat
effect
addit
examin
chang
gene
express
profil
pbmc
sar
patient
receiv
ifn
treatment
identifi
subset
ifnrespons
gene
whose
differenti
express
may
influenc
resolut
diseas
murin
lung
fibroblast
cell
maintain
dmem
heat
inactiv
fetal
calf
serum
penicillin
streptomycin
gl
lglutamin
murin
provid
dirk
gewert
wellcom
research
lab
kent
uk
pharmacolog
inhibitor
rottlerin
jak
inhibitor
obtain
calbiochem
polyclon
ab
phosphoryl
mapk
obtain
cell
signal
technolog
polyclon
ab
mapk
pkcd
obtain
santa
cruz
biotechnolog
polyclon
ab
upstat
biotechnolog
monoclon
ab
obtain
zyme
laboratori
stock
titer
pfuml
use
experi
cell
either
left
untreat
treat
prescrib
dose
murin
h
infect
h
cytoplasm
rna
isol
use
qiagen
rneasi
mini
kit
accord
manufactur
protocol
resolv
electrophoresi
denatur
agaroseformaldehyd
gel
northern
blot
analysi
perform
previous
describ
atplabel
oligonucleotid
probe
atc
att
cgc
ttt
acc
specif
bind
nucleotid
end
murin
rrna
use
detect
rrna
cleavag
product
assay
ifninduc
antivir
activ
monolay
cell
describ
previous
briefli
cell
seed
tissu
cultur
plate
dmem
contain
fc
h
appropri
dilut
ad
cell
incub
addit
h
medium
contain
ifn
aspir
appropri
dilut
volum
ad
cell
h
cell
fix
ethanol
stain
crystal
violet
solut
ethanol
destain
nacl
ethanol
ifninduc
inhibit
viral
replic
assess
read
absorb
nm
use
micropl
reader
molecular
devic
softwar
rel
infect
untreat
cell
immunoblot
cell
stimul
uml
indic
time
lyse
phosphoryl
lysi
buffer
immunoprecipit
immunoblot
use
ecl
enhanc
chemiluminesc
method
perform
describ
previous
experi
pharmacolog
inhibitor
use
cell
pretreat
min
indic
concentr
inhibitor
subsequ
treat
prior
lysi
phosphoryl
lysi
buffer
harvest
rna
real
time
pcr
cell
either
left
untreat
treat
indic
time
treat
pharmacolog
inhibitor
h
prior
treatment
h
cell
lyse
homogen
use
qiagen
qiashredd
column
rna
isol
perform
use
qiagen
rneasi
mini
kit
accord
manufactur
protocol
cdna
synthes
use
mg
rna
presenc
random
primer
amv
revers
tanscriptas
h
promega
reaction
compon
obtain
faststart
dna
master
sybr
greenplu
kit
roch
instrument
roch
correspond
softwar
use
reaction
pcr
perform
final
volum
primer
ml
templat
cdna
concentr
ngml
primer
set
follow
gapdh
forward
primer
gca
cca
cca
act
gct
revers
primer
tga
gcc
ctt
cca
caa
pkr
forward
tcc
tgt
gtg
gga
agt
revers
primer
gcc
aaa
agc
cag
agt
cct
forward
primer
gcg
ccc
ccc
atc
revers
primer
gac
cca
gga
cat
caa
standard
curv
establish
primer
set
refer
target
reaction
perform
sampl
serial
peripher
blood
mononuclear
cell
pbmc
sar
patient
includ
ifn
pilot
studi
analyz
gene
express
profil
use
affymetrix
plu
gene
chip
describ
tabl
patient
receiv
subcutan
ifn
addit
standard
care
corticosteroid
treatment
rna
extract
pbmc
pbmc
lyse
homogen
use
qiagen
qiashredd
column
rna
isol
perform
use
qiagen
rneasi
mini
kit
accord
manufactur
protocol
ensur
effect
inactiv
rnase
lysi
reagent
contain
denatur
guanidin
isothiocyan
highsalt
buffer
system
allow
rna
select
bind
silicagel
membran
spin
column
contamin
wash
away
total
cellular
rna
elut
water
total
rna
amplifi
use
ambion
ii
arna
amplif
kit
amplif
perform
accord
manufactur
protocol
briefli
first
round
amplif
ml
ng
total
rna
use
convert
arna
arna
concentr
calcul
mg
amplifi
rna
arna
use
second
round
amplif
second
round
amplif
biotin
label
ntp
incorpor
crna
mg
biotinyl
crna
sent
affymetrix
gene
express
analysi
centr
appli
genom
microarray
facil
hospit
sick
children
toronto
ontario
addit
sent
bioanalyz
analysi
gene
express
analysi
perform
hybrid
cdna
gene
chip
plu
chip
code
probe
specif
effect
ifn
treatment
gene
express
analyz
use
microarray
analysi
softwar
array
gene
express
profil
analyz
use
gcrma
analysi
method
use
basic
algorithm
order
identifi
gene
whose
express
alteredregul
sampl
array
compar
basal
level
express
chip
list
gene
use
gene
express
level
measur
day
rel
onset
symptom
design
basal
sar
patient
new
list
gene
whose
express
regul
greater
three
fold
ifn
treatment
obtain
data
panel
b
figur
show
protect
cell
rna
cleavag
cytopath
effect
cpe
examin
influenc
specif
ifn
activ
signal
effector
protect
infect
studi
effect
number
pharmacolog
inhibitor
target
specif
signal
molecul
high
affin
bind
ifn
ifnar
lead
phosphorylationactiv
receptorassoci
jak
cell
treat
inhibitor
jak
inhibitor
led
reduct
induc
tyrosin
phosphoryl
figur
addit
observ
reduct
ifninduc
tyrosin
phosphoryl
figur
cell
treat
jak
inhibitor
prior
ifn
treatment
infect
observ
reduct
ifninduc
protect
infect
figur
neg
control
examin
effect
inhibitor
specif
inhibit
anticip
treat
cell
influenc
activ
figur
mapk
pathway
essenti
induct
antivir
respons
ifn
hepat
c
viru
vesicular
stomat
viru
encephalomyocard
viru
infect
examin
import
ifninduc
mapk
signal
protect
infect
cell
treat
prior
reduc
phosphoryl
mapk
figur
ifninduc
protect
infect
figur
subsequ
experi
use
inhibitor
rottlerin
studi
influenc
ifninduc
activ
rottlerin
decreas
induc
tyrosin
phosphoryl
figur
addit
rottlerin
reduc
activ
figur
expect
inhibit
decreas
induc
tyrosin
phosphoryl
figur
sinc
inhibit
activ
block
phosphoryl
ifninduc
control
viral
replic
effect
regul
transcript
activ
key
interferon
stimul
gene
isg
rnadepend
protein
kinas
pkr
oligoadenyl
synthetas
oa
endoribonucleas
l
rnase
l
murin
cell
virusinduc
activ
toll
like
receptor
lead
transcript
activ
therefor
infect
per
se
induc
transcript
activ
ifn
lead
subsequ
transcript
activ
pkr
accordingli
cell
infect
rna
harvest
differ
time
point
extent
gene
express
analyz
use
real
time
pcr
time
cours
studi
observ
minim
transcript
activ
pkr
figur
subsequ
experi
examin
effect
treatment
transcript
activ
similar
time
cours
studi
cell
treat
uml
transcript
activ
pkr
observ
figur
subsequ
experi
examin
effect
inhibit
induc
activ
mapk
induc
transcript
activ
pkr
gene
express
cell
treat
jak
inhibitor
mm
rottlerin
h
uml
h
rna
harvest
gene
express
pkr
examin
h
time
point
select
base
data
figur
name
maxim
ifninduc
transcript
activ
gene
attain
notabl
inhibit
ifninduc
activ
mapk
effect
reduc
ifninduc
gene
express
pkr
figur
absenc
clear
caus
effect
relationship
pkr
gene
express
ifninduc
activ
subsequ
examin
signatur
pattern
gene
express
pbmc
sar
studi
patient
treat
ifn
toronto
outbreak
comparison
measur
gene
express
pbmc
sar
patient
treat
corticosteroid
alon
see
materi
method
pbmc
sampl
day
postonset
symptom
ifntreat
sar
patient
day
pbmc
sampl
repres
baselin
absenc
ifn
treatment
wherea
day
correspond
day
rel
start
ifn
treatment
data
tabl
reveal
list
gene
express
differenti
ifntreat
sar
patient
nonifn
treat
patient
use
cutoff
b
chang
express
rel
basal
express
level
day
postonset
symptom
figur
differenti
express
gene
cluster
indic
high
low
gene
express
use
redgreen
colour
scale
show
rel
rang
notabl
analys
identifi
gene
upregul
gene
downregul
ifntreat
patient
accord
criteria
upregul
gene
includ
interleukin
defensin
alpha
alpha
chemoattract
neutrophil
induc
neutrophil
degranul
enhanc
defensin
releas
neutrophil
defensin
potent
antimicrobi
peptid
shown
exhibit
antivir
activ
envelop
virus
hiv
downregul
gene
includ
proteinkinas
repressor
prkrir
act
prevent
pkr
synthesi
express
exportin
also
downregul
pbmc
ifntreat
sar
patient
transport
receptor
mediat
nuclear
export
protein
interact
rev
protein
hiv
suggest
potenti
inhibit
nuclear
activ
associ
viral
replic
addit
express
gene
encod
rna
bind
protein
helicas
includ
also
downregul
support
inhibitori
effect
viral
replic
intermedi
interestingli
dead
box
protein
implic
facilit
hiv
view
altogeth
implic
ifn
treatment
affect
gene
express
pbmc
sar
patient
promot
direct
antivir
effect
inhibit
viral
replic
use
murin
vitro
model
sar
name
infect
murin
lung
fibroblast
cell
investig
influenc
variou
signal
molecul
mediat
antivir
protect
find
suggest
mapk
play
import
role
activ
lower
dose
pretreat
cell
jak
inhibitor
complet
abrog
protect
effect
sinc
activ
earli
postreceptor
activ
event
surpris
abrog
upstream
effector
ifnreceptor
signal
cascad
profound
effect
subsequ
downstream
signal
event
biolog
respons
contrast
higher
dose
inhibit
inhibit
ifninduc
antivir
activ
greater
extent
impli
isg
activ
necessari
ifninduc
activ
notabl
antivir
activ
unlik
exclus
attribut
activ
mapk
demonstr
cell
treat
induc
transcript
activ
pkr
stark
contrast
neglig
activ
observ
cell
infect
infer
data
infect
per
se
may
prevent
activ
ifn
system
inde
mani
differ
virus
evad
immun
respons
interf
transcript
activ
gene
notabl
order
escap
activ
ifn
system
sarscov
appear
block
step
earli
nuclear
transport
transcript
factor
essenti
promot
activ
inhibit
ifninduc
activ
mapk
shown
also
influenc
transcript
activ
pkr
effect
unlik
wholli
attribut
inhibitori
activ
pkr
inde
mani
ifninduc
gene
identifi
encod
factor
implic
ifninduc
antivir
respons
interestingli
analyz
signatur
pattern
gene
express
pbmc
sar
patient
receiv
ifn
compar
patient
observ
trend
differenti
gene
express
ifntreat
patient
suggest
antimicrobi
activ
ongo
studi
investig
contribut
specif
gene
product
antivir
activ
conclus
data
suggest
activ
mapk
involv
gener
activ
control
ifninduc
transcript
activ
minim
pkr
implic
ifninduc
activ
specif
signal
molecul
lead
transcript
regul
subset
isg
determin
direct
antivir
activ
coronaviru
infect
